- Source : Press Release
- Date : 2021-02-25
- Companies : Merck KGaA
Merck to Provide CDMO Services to Alteogen
Alteogen said Thursday that it has secured Merck's contract development and manufacturing organization (CDMO) services for its ALT-B4, a human hyaluronidase made by using Alteogen's Hybrozyme technology.
Under the accord, Merck will provide its BioReliance End-to-End Solutions. This program helps the clinical and commercialization process of biopharmaceutical companies. Merck will transfer Alteogen's existing manufacturing process to Merck's cGMP (current good manufacturing practice) facility in Martillac, France.
The facility will provide CDMO services, including human hyaluronidase production used in subcutaneous injection (SC) antibody therapy.
Alteogen stressed that the contract was part of its preparation work to supply clinical samples and raw materials for commercial production to global pharmaceutical companies affiliated with the company.
"We believe that Merck's French facility is a scale suitable for technology transfer and production of ALT-B4," a company official said. "Through this contract, the company has laid the foundation to supply products to global markets such as Europe."
Andrew Bulpin, Merck's head of process solutions, said, "There is a growing demand for subcutaneous injections that enable self-treatment, improve quality of life and reduce medical costs. Therefore, the agreement could advance Merck's strategy to provide a revolutionary next-generation biopharmaceutical that allows simple subcutaneous administration of biologics that requires intravenous administration in large quantities.”